Health

Thailand, Philippines sign for AstraZeneca COVID-19 vaccine

Fitness & Health:

Thailand has signed a deal to procure 26 million doses of a trial coronavirus vaccine developed by pharmaceutical firm AstraZeneca in collaboration with Oxford University

The doses would cover 13 million people in a population of about 69 million.

Thailand’s National Vaccine Institute signed a non-refundable advance market commitment contract worth 2.38 billion baht ($79 million) with AstraZeneca to reserve the supply of the vaccine candidate. Another 3.67 billion baht ($121 million) agreement for the purchase of the trial vaccine, known as AZD1222, was signed by the Health Ministry’s Disease Control Department.

“We have followed the vaccine manufacturers globally, but this group has achieved very high progress,” Thai Prime Minister Prayuth Chan-ocha said at the signing. “They are likely to be able to produce the vaccine early next year. Most importantly, we have to get ourselves ready for the domestic process including packaging and logistics.”

RELATED:  UK leader to end England's national lockdown on Dec. 2

Government spokesperson Anucha Burapachaisri said officials are still considering how to prioritize vaccine recipients. “Those who work closely with COVID-19 patients, for example, doctors and nurses, should be among the first people. But this needs further discussion,” he said.

Oxford and AstraZeneca reported Monday that their trial vaccine appeared to be 62% effective in people who received two doses, and 90% effective when volunteers were given a half dose followed by a full dose.

They did not mention at the time, but later acknowledged, that a manufacturing issue had resulted in “a half dose of the vaccine being administered as the first dose” to some participants, a development that led to criticism that its test results were flawed.

AstraZeneca has said it plans to conduct a new global clinical trial to make a fresh assessment of the vaccine’s efficacy.

Under a separate deal in October, the Health Ministry, Siam Bioscience Co. and the SCG business conglomerate signed a letter of intent with AstraZeneca on the manufacturing and supply of the AZD1222 vaccine candidate. It would allow Siam Bioscience to produce the vaccine at its own plant, with a starting date targeted for the middle of next year.

RELATED:  Human migration patterns connected to vitamin D deficiencies today

Siam Bioscience said that if plans proceed smoothly, Thailand would become the first country in Southeast Asia to produce the vaccine.

Business leader Jose Concepcion III said the vaccine is expected to be delivered in the second quarter of next year and would cover about 1 million people, but did not disclose other details.

The purchase would be crucial in restoring business confidence that has been shattered by months of the pandemic and lockdowns, he said.

“We want an end to this nightmare and this is the best alternative we have,” Concepcion told an online news conference after the signing, describing it as an opportunity to open up the economy again.

RELATED:  Massive US protests raise fears of new virus outbreaks

The Philippine government says it’s targeting about 60 million Filipinos to be vaccinated against the coronavirus over about two years starting next year. The action, at a cost of more than 73 billion pesos ($1.4 billion) is aimed at developing immunity in a majority of the population. The Philippines has recorded 425,918 confirmed cases of the coronavirus, including 8,255 deaths.

——-

Associated Press correspondent Jim Gomez in Manila contributed to this report.

DISCLAIMER:-If article is on fitness, health tips, beauty, tips-tricks care like recommendation, then check for DISCLAIMER in T&C.

Health News Today & Latest Medical News More Updates

Today News || Latest News || World News || US Politics || Health News || Technology News || Education News

Source

Tags
Show More

Related Articles

Back to top button
Close